A new era for innovation, prevention, and patient access to modern treatments is being signalled by the European Commission’s presentation of an ambitious package of measures aimed at strengthening the competitiveness of Europe’s health sector. The package, unveiled in Brussels, centres on three key pillars: the Biotech Act, the revision of rules for medical devices, and the “Safe Hearts” plan for cardiovascular health. Its goals are to bolster the resilience of health systems, support innovation, and reduce inequalities among member states, at a time when Europe seeks to compete with the US and Asia in cutting-edge sectors.
For smaller markets such as Cyprus, with a limited population and longstanding challenges in translating research into practice, the question remains whether this represents a genuine opportunity or another European strategy destined to remain on paper without national readiness.
From biotechnology to everyday care
At a practical level, the Biotech Act aims to simplify the regulatory environment and accelerate the transition from research to market, facilitating clinical trials and access to funding tools, including via the European Investment Bank. For Cyprus, this could mean greater participation in European research networks and new opportunities for startups, provided there is national strategy and administrative support.
The “Safe Hearts” plan also addresses a pressing issue for Cypriot society. Cardiovascular diseases are a leading cause of mortality, with risk factors such as obesity, smoking, and diabetes occurring with worrying frequency. The EU’s focus on prevention, early diagnosis, and the use of digital tools could act as a lever for policy action in Cyprus, where the absence of comprehensive patient registries remains a major gap.
Finally, the simplification of rules for medical devices is particularly relevant for a country almost entirely dependent on imports. Strengthening the role of the European Medicines Agency and creating a list of critical devices may reduce delays and shortages, improving patient safety and access.
Why this matters for Cyprus
Although European policies are often designed with larger markets in mind, Cyprus has specific reasons to follow these developments closely. The country possesses considerable scientific talent and emerging research centres, but lacks critical infrastructure such as large-scale clinical trials, systematic use of health data, and mechanisms to transfer know-how from universities to industry. Delays in access to innovative therapies and medical devices remain a persistent issue for patients and healthcare professionals.
Dr Gregory Papagregoriou, a molecular biologist and geneticist at the University of Cyprus and head of the biobank.cy Centre of Excellence, told Politis that initiatives such as the European Commission’s package are particularly valuable for countries like Cyprus. While Cyprus has highly skilled research talent, it lags in key areas for translating scientific achievements from the lab to industry.
He stressed that “investment in translational research will, in the long term, reduce resource needs for health systems and improve population health and sustainability.”
As an example, he cited pharmaceutical manufacturing. While Cyprus has strong, internationally recognised pharmaceutical companies producing a wide range of generics, industrial research for developing and clinically testing new, improved, or targeted drugs lags behind. Achieving this requires infrastructure and regulations to bridge academic and industrial research, allowing scientific findings to progress through clinical trials, licensing, and production. In this context, establishing biotech startups with private, public, and EU funding to support high-risk research can be a key first step in technology transfer, job creation, and industrial capacity building, ultimately benefiting patients.
Dr Papagregoriou also highlighted the broader benefits of investing in both basic and translational research, stressing the importance of professional continuity for researchers so that Cyprus can become a hub for talented scientists. “Research is a continuous process,” he said, warning that early-career researchers with only short-term funding risk losing what they have built if support is not renewed, resulting in the loss of both investment and scientific talent.
He concluded by noting the package’s potential to boost clinical trials in small countries. “The Cypriot population is ideal for such efforts,” he said, citing both population homogeneity and short distances, which allow greater reliability in studies, effective disease monitoring, faster evaluation of interventions, and immediate access for Cypriot patients to innovative therapies.
This article was originally published in the Politis daily newspaper.